Objective To conduct a comprehensive clinical evaluation of intravenous iron agents, and to provide a reference for their rational clinical application, the selection of drug formularies in medical institutions, and the formulation of national pharmaceutical policies.

Methods This consensus was developed under the leadership of Yantai Yuhuangding Hospital, in collaboration with 101 pharmacy and clinical medicine experts from 89 tertiary hospitals across different provinces and cities in China. Based on evidence-based medicine, methods such as the Delphi method and multi-criteria decision analysis were employed. Through seminars and expert consultations, a comprehensive clinical evaluation index system for intravenous iron agents was established across six dimensions: effectiveness, safety, economy, suitability, accessibility, and innovation. A comprehensive clinical evaluation was subsequently conducted on four types of intravenous iron agents.

Results A scientific, standardized, and practial comprehensive clinical evaluation index system for intravenous iron agents was constructed and quantitatively scored across the six dimensions of effectiveness, safety, economy, suitability, accessibility, and innovation. The total scores, ranked from highest to lowest, were as follows: iron isomaltoside injection (72.1), ferric carboxymaltose injection (71.3), iron sucrose injection (55.5), and iron dextran injection (54.8).

Conclusions This consensus provides recommendations and decision-making support for the rational clinical application of intravenous iron agents, the selection of drug formularies in medical institutions, and the formulation of national pharmaceutical policies.

1. GardnerWM, RazoC, MchughTA, et al. Prevalence, years lived with disability, and trends in anaemia burden by severity and cause, 1990-2021: findings from the Global Burden of Disease Study 2021[J]. Lancet Haematol, 2023, 10(9): e713-e734. DOI: 10.1016/s2352-3026(23)00160-6.

2. 中华医学会血液学分会红细胞疾病(贫血)学组. 铁缺乏症和缺铁性贫血诊治和预防的多学科专家共识(2022年版)[J]. 中华医学杂志, 2022, 102(41): 3246-3256.Red Cell Disease (Anemia) Group, Hematology Branch, Chinese Medical Association. Multidisciplinary expert consensus on the diagnosis, treatment, and prevention of iron deficiency and iron‑deficiency anemia (2022 edition)[J]. National Medical Journal of China, 2022, 102(41): 3246‑3256. DOI: 10.3760/cma.j.cn112137-20220621-01361.

3. 药物政策与基本药物制度司. 国家卫生健康委办公厅关于规范开展药品临床综合评价工作的通知[EB/OL]. (2021-07-28) [2026-04-23]. https://www.nhc.gov.cn/yaozs/c100097/202107/d2a45e6ae041423f950b3865e43f5ef6.shtml.

4. 国家卫生健康委药物政策与基本药物制度司. 关于开展药品使用监测和临床综合评价工作的通知[EB/OL]. (2019-04-09) [2026-04-23]. https://www.nhc.gov.cn/yaozs/c100097/201904/6bc8f273684845d3ab76fed841eb42d2.shtml.

5. 国家卫生健康委卫生发展研究中心. 关于发布《药品临床综合评价质量控制指南(2024年版试行)》的通知[EB/OL]. (2024-12-31) [2026-04-23]. http://nhei.cn/nhei/znfb/202412/d33db3fcddf94daeabe49cfa95fa24f9.shtml.

6. 赵志刚, 董占军, 刘建平. 中国医疗机构药品评价与遴选快速指南(第三版)[J]. 医药导报, 2026, 45(1): 1-9.ZhaoZG, DongZJ, LiuJP. A quick guideline for drug evaluation and selection in Chinese medical institutions (the third edition)[J]. Herald of Medicine, 2026, 45(1): 1-9. DOI: 10.3870/j.issn.1004-0781.2026.01.001.

7. 国家心血管病中心, 国家心血管病专家委员会心力衰竭专业委员会, 中国医师协会心力衰竭专业委员会, 等. 国家心力衰竭指南2023[J]. 中华心力衰竭和心肌病杂志, 2023, 7(4): 215-311.National Center for Cardiovascular Diseases, China National Heart Failure Society, Chinese Heart Failure Association of Chinese Medical Doctor Association, et al. China national heart failure guideline 2023[J]. Chinese Journal of Heart Failure and Cardiomyopathy, 2023, 7(4): 215-311. DOI: 10.3760/cma.j.issn.101460-20231209-00052.

8. 中华医学会肾脏病学分会, 中关村肾病血液净化创新联盟. 中国透析患者慢性心力衰竭管理指南[J]. 中华肾脏病杂志, 2022, 38(5): 465-496.Chinese Society of Nephrology, Zhongguancun Nephrology＆Blood Purification Innovation Alliance. Guidelines for the management of chronic heart failure in dialysis patients in China[J]. Chinese Journal of Nephrology, 2022, 38(5): 465‑496. DOI: 10.3760/cma.j.cn441217-20210812-00068.

9. 中华医学会, 中华医学会杂志社, 中华医学会全科医学分会, 等. 中国心力衰竭基层诊疗与管理指南(2024年)[J]. 中华全科医师杂志, 2024, 23(6): 549-577.Chinese Medical Association, Chinese Medical Association Publishing House, Chinese Society of General Practice, et al. Chinese guideline for the diagnosis and management of heart failure in primary care (2024)[J]. Chinese Journal of General Practitioners, 2024, 23(6): 549‑577. DOI: 10.3760/cma.j.cn114798-20231227-00476.

10. McdonaghTA, MetraM, AdamoM, et al. 2023 Focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure[J]. Eur Heart J, 2023, 44(37): 3627-3639. DOI: 10.1093/eurheartj/ehad195.

11. YancyCW, JessupM, BozkurtB, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America[J]. Circulation, 2017, 136(6): e137-e161. DOI: 10.1161/cir.000000 0000000509.

12. 中华医学会骨科学分会创伤骨科学组, 中华医学会骨科学分会外固定与肢体重建学组, 中华医学会创伤学分会, 等. 中国创伤骨科围手术期血液管理临床指南(2023)[J]. 中华创伤骨科杂志, 2023, 25(3): 185-192.Traumatic Orthopaedics Group, Society of Orthopaedics, Chinese Medical Association, Group of External Fixation and Limb Reconstruction, Society of Orthopaedics, Chinese Medical Association, Society of Traumatology, Chinese Medical Association, et al. Chinese clinical guidelines for perioperative blood management in traumatology and orthopaedics (2023)[J]. Chinese Journal of Orthopaedic Trauma, 2023, 25(3): 185‑192. DOI: 10.3760/cma.j.cn115530-20230303-00115.

13. 康鹏德, 黄强, 沈慧勇, 等. 中国骨科手术围手术期贫血诊疗指南[J]. 中华骨与关节外科杂志, 2019, 12(11): 833-840.KangPD, HuangQ, ShenHY, et al. Guidelines for diagnosis and treatment of anemia during perioperative period of orthopedic surgery in China[J]. Chinese Journal of Bone and Joint Surgery, 2019, 12(11): 833‑840. DOI: 10.3969/j.issn.2095-9958.2019.11.01.

14. Centre for Perioperative Care. Guideline for the Management of Anaemia in the Perioperative Pathway[EB/OL]. (2022-09) [2026-04-23]. https://cpoc.org.uk/sites/cpoc/files/documents/2022-09/1.%20CPOC_GuidelinefortheManagementofAnaemia_September2022.pdf.

15. KietaiblS, AhmedA, AfshariA, et al. Management of severe peri-operative bleeding: guidelines from the European Society of Anaesthesiology and Intensive Care[J]. Eur J Anaesthesiol, 2023, 40(4): 226-304. DOI: 10.1097/eja.0000000000001803.

16. TibiP, McclureRS, HuangJ, et al. STS/SCA/AmSECT/SABM update to the clinical practice guidelines on patient blood management[J]. Ann Thorac Surg, 2021, 112(3): 981-1004. DOI: 10.1016/j.athoracsur.2021.03.033.

17. ThompsonA, FleischmannKE, SmilowitzNR, et al. 2024 AHA/ACC/ACS/ASNC/HRS/SCA/SCCT/SCMR/SVM guideline for perioperative cardiovascular management for noncardiac surgery[J]. J Am Coll Cardiol, 2024, 84(19): 1869-1969. DOI: 10.1016/j.jacc.2024.06.013.

18. 中华医学会围产医学分会. 妊娠期铁缺乏和缺铁性贫血诊治指南[J]. 中华围产医学杂志, 2014, 17(7): 451-454.Chinese Society of Perinatal Medicine. Guideline for the diagnosis and treatment of iron deficiency and iron‑deficiency anemia during pregnancy[J]. Chinese Journal of Perinatal Medicine, 2014, 17(7): 451‑454. DOI: 10.3760/cma.j.issn.1007-9408.2014.07.006.

19. 赵岩, 刘彩霞, 魏军, 等. 双胎妊娠期缺铁性贫血诊治及保健指南(2023年版)[J]. 中国实用妇科与产科杂志, 2023, 39(4): 419-430.ZhaoY, LiuCX, WeiJ, et al. Diagnosis, treatment and healthcare guidelines for iron-deficiency anemia in twin pregnancy (2023 edition)[J]. Chinese Journal of Practical Gynecology and Obstetrics, 2023, 39(4): 419‑430. DOI: 10.19538/j.fk2023040110.

20. PavordS, DaruJ, PrasannanN, et al. UK guidelines on the management of iron deficiency in pregnancy[J]. Br J Haematol, 2019, 188(6): 819-830. DOI: 10.1111/bjh.16221.

21. 中国临床肿瘤学会, 肿瘤相关性贫血临床实践指南2024[M]. 北京: 人民卫生出版社, 2024.Chinese Society of Clinical Oncology. Clinical practice guidelines for cancer‑related anemia 2024[M]. Beijing: People's Medical Publishing House, 2024.

22. SbranaA, AntonuzzoA, BrunelloA, et al. Management of anemia in patients with cancer: 2019 Italian Association of Medical Oncology (AIOM) guidelines[J]. Tumori, 2020, 106(5): 337-345. DOI: 10.1177/0300891620921942.

23. National Comprehensive Cancer Network. Hematopoietic growth factors[EB/OL]. (2025-12-05) [2026-04-23]. https://www.nccn.org/professionals/physician_gls/pdf/growthfactors.pdf.

24. MartinelliM, FiorettiMT, AloiM, et al. Diagnosis and management of anemia in pediatric inflammatory bowel diseases: clinical practice guidelines on behalf of the SIGENP IBD working group[J]. Dig Liver Dis, 2024, 56(8): 1257-1269. DOI: 10.1016/j.dld.2024.02.016.

25. GordonH, BurischJ, EllulP, et al. ECCO guidelines on extraintestinal manifestations in inflammatory bowel disease[J]. J Crohns Colitis, 2024, 18(1): 1-37. DOI: 10.1093/ecco-jcc/jjad108.

26. GoyalA, ZhengY, AlbenbergLG, et al. Anemia in children with inflammatory bowel disease[J]. J Pediatr Gastroenterol Nutr, 2020, 71(4): 563-582. DOI: 10.1097/mpg.0000000000002885.

27. SnookJ, BhalaN, BealesILP, et al. British Society of Gastroenterology guidelines for the management of iron deficiency anaemia in adults[J]. Gut, 2021, 70(11): 2030-2051. DOI: 10.1136/gutjnl-2021-325210.

28. DelougheryTG, JacksonCS, KoCW, et al. AGA clinical practice update on management of iron deficiency anemia: expert Review[J]. Clin Gastroenterol Hepatol, 2024, 22(8): 1575-1583. DOI: 10.1016/j.cgh.2024.03.046.

29. 中国医师协会肾脏内科医师分会肾性贫血指南工作组. 中国肾性贫血诊治临床实践指南[J]. 中华医学杂志, 2021, 101(20): 1463-1502.Renal Anemia Guideline Working Group, Nephrologist Branch of Chinese Medical Doctor Association. Clinical practice guideline for the diagnosis and treatment of renal anemia in China[J]. National Medical Journal of China, 2021, 101(20): 1463‑1502. DOI: 10.3760/cma.j.cn112137-20210201-00309.

30. 《铁剂在慢性肾脏病贫血患者中应用的临床实践指南》编写委员会. 铁剂在慢性肾脏病贫血患者中应用的临床实践指南[J]. 中国血液净化, 2022, 21(增刊): 17-40.Committee of Clinical Practice Guideline for Use of Iron on Anemia in Chronic Kidney Disease. Clinical practice guideline for use of iron on anemia in chronic kidney disease[J]. Chinese Journal of Blood Purification, 2022, 21(Suppl): 17‑40. DOI: 10.3969/j.issn.1671-4091.2022.S.002.

31. Kidney AssociationUK. Clinical practice guideline: anaemia of chronic kidney disease[EB/OL]. (2024-09) [2026-04-23]. https://www.ukkidney.org/sites/default/files/FINAL%20VERSION%20-%20%20UKKA%20ANAEMIA%20OF%20CKD%20GUIDELINE%20-%20Sept%202024.pdf.

32. National Institute for Health and Care Excellence. Chronic kidney disease: assessment and management[EB/OL]. (2021-08-25) [2026-04-23]. https://www.nice.org.uk/guidance/ng203.

33. TonelliM, BernsJS, BozkurtB, et al. KDIGO 2026 clinical practice guideline for the management of anemia in Chronic Kidney Disease (CKD)[J]. Kidney Int, 2026, 109(1): S1-S99. DOI: 10.1016/j.kint.2025.06.006.

34. 陈斌, 洪梅, 曹小雄, 等. 老年缺铁性贫血慢病管理指南[J]. 中西医结合研究, 2024, 16(6): 383-394.ChenB, HongM, CaoXX, et al. Guideline for chronic disease management of iron‑deficiency anemia in the elderly[J]. Research of Integrated Traditional Chinese and Western Medicine, 2024, 16(6): 383‑394.  DOI: 10.3969/j.issn.1674-4616.2024.06.005.

35. TanriverdiLH, SariciA. Efficacy, safety, and tolerability of ferric carboxymaltose and iron sucrose in iron deficiency anemia: a systematic review and Meta-analysis of randomized controlled trials[J]. Turk J Haematol, 2025, 42(2): 119-135. DOI: 10.4274/tjh.galenos.2025.2025.0034.

36. GupteS, MukhopadhyayA, PuriM, et al. A meta-analysis of ferric carboxymaltose versus other intravenous iron preparations for the management of iron deficiency anemia during pregnancy[J]. Rev Bras Ginecol Obstet, 2024, 46: e-rbgo21. DOI: 10.61622/rbgo/2024AO21.

37. SrimathiG, RevathyR, BagepallyBS, et al. Clinical effectiveness of ferric carboxymaltose (iv) versus iron sucrose (iv) in treatment of iron deficiency anaemia in pregnancy: a systematic review and Meta-analysis[J]. Indian J Med Res, 2024, 159(1): 62-70. DOI: 10.4103/ijmr.ijmr_246_23.

38. SinghY, BharadwajMK, PatrikarS. Comparative analysis of injection ferric carboxymaltose vs iron sucrose for treatment of iron-deficiency anemia in pregnancy: systematic review and Meta-analysis[J]. J South Asian Fed Obstet Gynaecol, 2023, 15(5): 629-636. DOI: 10.5005/jp-journals-10006-2311.

39. RogozińskaE, DaruJ, NicolaidesM, et al. Iron preparations for women of reproductive age with iron deficiency anaemia in pregnancy (FRIDA): a systematic review and network Meta-analysis[J]. Lancet Haematol, 2021, 8(7): e503-e512. DOI: 10.1016/s2352-3026(21)00137-x.

40. ShinHW, GoDY, LeeSW, et al. Comparative efficacy and safety of intravenous ferric carboxymaltose and iron sucrose for iron deficiency anemia in obstetric and gynecologic patients[J]. Medicine, 2021, 100(20): e24571. DOI: 10.1097/md.0000000000024571.

41. XueQ, ZhangB, XingZ, et al. Efficacy and safety of intravenous iron supplementation for perioperative iron deficiency anemia: a systematic review and network Meta-analysis of randomized controlled trials[J]. J Clin Anesth, 2026, 108: 112062. DOI: 10.1016/j.jclinane.2025.112062.

42. 黄媛, 苏娜, 李丹, 等. 不同静脉铁剂治疗贫血效果的网状meta分析[J]. 临床药物治疗杂志, 2022, 20(12): 29-34. [HuangY, SuN, LiD, et al. Network Meta-analysis of different intravenous irons in the treatment of anemia[J]. Clinical Medication Journal, 2022, 20(12): 29‑34.DOI: 10.3969/j.issn.1672-3384.2022.12.006.

43. ShiL, ZhaoY, RaoA. Comparison of iron isomaltoside ferumoxytol with iron sucrose for iron deficiency anemia: a Meta-analysis of randomized controlled trials[J]. Afr Health Sci, 2023, 23(3): 205-212. DOI: 10.4314/ahs.v23i3.25.

44. DanielsonBG, SalmonsonT, DerendorfH, et al. Pharmacokinetics of iron (III)-hydroxide sucrose complex after a single intravenous dose in healthy volunteers[J]. Arzneimittelforschung, 1996, 46(6): 615-619. https://www.semanticscholar.org/paper/Pharmacokinetics-of-Iron-Isomaltoside1000-in-with-5-Gupta-Larson/6ff7dae8cf801 7752c5c8511c82b60cc1e1c3cac.

45. GuptaDR, LarsonDS, ThomsenLL, et al. Pharmacokinetics of iron isomaltoside 1000 in with stage 5 chronic kidney disease on dialysis therapy[J]. J Drug Metab Toxicol, 2013, 4(3): 1000152. DOI: 10.4172/2157-7609.1000152.

46. ThomsenLL, NordfjeldK, AndreasenH. Pharmacokinetics of iron isomaltoside 1000 in patients with inflammatory bowel disease[J]. Drug Des Devel Ther, 2012, 6: 43-51. DOI: 10.2147/dddt.S30015.

47. DingY, ZhuX, LiX, et al. Pharmacokinetic, pharmacodynamic, and safety profiles of ferric carboxymaltose in Chinese patients with iron-deficiency anemia[J]. Clin Ther, 2020, 42(2): 276-285. DOI: 10.1016/j.clinthera.2019.12.010.

48. GeisserP, BurckhardtS. The pharmacokinetics and pharmaco-dynamics of iron preparations[J]. Pharmaceutics, 2011, 3(1): 12-33. DOI: 10.3390/pharmaceutics3010012.

49. RamptonD, FolkersenJ, FishbaneS, et al. Hypersensitivity reactions to intravenous iron: guidance for risk minimization and management[J]. Haematologica, 2014, 99(11): 1671-1676. DOI: 10.3324/haematol.2014.111492.

50. European Medicines Agency. Intravenous iron-containing medicinal products[EB/OL]. (2013-11-14) [2026-04-23]. https://www.ema.europa.eu/en/medicines/human/referrals/intravenous-iron-containing-medicinal-products.

51. BhandariS, KalraPA, BerkowitzM, et al. Safety and efficacy of iron isomaltoside 1000/ferric derisomaltose versus iron sucrose in patients with chronic kidney disease: the FERWON-NEPHRO randomized, open-label, comparative trial[J]. Nephrol Dial Transplant, 2021, 36(1): 111-120. DOI: 10.1093/ndt/gfaa011.

52. AuerbachM, HenryD, DermanRJ, et al. A prospective, multi-center, randomized comparison of iron isomaltoside 1000 versus iron sucrose in patients with iron deficiency anemia; the FERWON-IDA trial[J]. Am J Hematol, 2019, 94(9): 1007-1014. DOI: 10.1002/ajh.25564.

53. KennedyNA, AchebeMM, BiggarP, et al. A systematic literature review and meta-analysis of the incidence of serious or severe hypersensitivity reactions after administration of ferric derisomaltose or ferric carboxymaltose[J]. Int J Clin Pharm, 2023, 45(3): 604-612. DOI: 10.1007/s11096-023-01548-2.

54. WangC, GrahamDJ, KaneRC, et al. Comparative risk of anaphylactic reactions associated with intravenous iron products[J]. JAMA, 2015, 314(19): 2062-2068. DOI: 10.1001/jama.2015.15572.

55. 中国药理学会药源性疾病学专业委员会, 广东省药学会. 静脉铁剂的临床应用和药学监护专家共识(2024)[J]. 药物不良反应杂志, 2025, 27(3): 129-141.Chinese Pharmacological Society Professional Committee of Drug‑induced Diseases, Guangdong Pharmaceutical Association. Expert consensus of clinical application and pharmaceutical care for intravenous iron agents (2024)[J]. Adverse Drug Reactions Journal, 2025, 27(3): 129‑141. DOI: 10.3760/cma.j.cn114015-20240929-00070.

56. LucasS, GargM. Intravenous iron: an update[J]. Intern Med J, 2024, 54(1): 26-34. DOI: 10.1111/imj.16184.

57. Van DorenL, SteinheiserM, BoykinK, et al. Expert consensus guidelines: intravenous iron uses, formulations, administration, and management of reactions[J]. Am J Hematol, 2024, 99(7): 1338-1348. DOI: 10.1002/ajh.27220.

58. Clinicaltrials.Gov. Hypophosphatemia with ferric carboxymaltose vs. iron dextran in iron deficiency secondary to heavy uterine bleeding[EB/OL]. (2018-02-19) [2026-04-14]. https://clinicaltrials.gov/study/NCT01307007?tab=researcher.

59. AdkinsonNF, StraussWE, MacdougallIC, et al. Comparative safety of intravenous ferumoxytol versus ferric carboxymaltose in iron deficiency anemia: a randomized trial[J]. Am J Hematol, 2018, 93(5): 683-690. DOI: 10.1002/ajh.25060.

60. WolfM, RubinJ, AchebeM, et al. Effects of iron isomaltoside vs ferric carboxymaltose on hypophosphatemia in iron-deficiency anemia: two randomized clinical trials[J]. JAMA, 2020, 323(5): 432-443. DOI: 10.1001/jama.2019.22450.

61. WolfM, ChertowGM, MacdougallIC, et al. Randomized trial of intravenous iron-induced hypophosphatemia[J]. JCI Insight, 2018, 3(23): e124486. DOI: 10.1172/jci.insight.124486.

62. DermanR, RomanE, ModianoMR, et al. A randomized trial of iron isomaltoside versus iron sucrose in patients with iron deficiency anemia[J]. Am J Hematol, 2017, 92(3): 286-291. DOI: 10.1002/ajh.24633.

63. BellosI, FrountzasM, PergialiotisV. Comparative risk of hypophosphatemia following the administration of intravenous iron formulations: a network Meta-analysis[J]. Transfus Med Rev, 2020, 34(3): 188-194. DOI: 10.1016/j.tmrv.2020.07.002.

64. 国家药品监督管理局. EMA评估低分子右旋糖酐铁的过敏反应风险[EB/OL]. (2010-11-11) [2026-04-23]. https://www.nmpa.gov.cn/xxgk/yjjsh/ywjjkx/20101111120001328.html.

65. 国家药品监督管理局. 英国警示静脉用铁制剂严重超敏反应风险[EB/OL]. (2014-01-08) [2026-04-23]. https://www.nmpa.gov.cn/xxgk/yjjsh/ywjjkx/20140108120001192.html.

66. Medicines and Healthcare products Regulatory Agency. Ferric carboxymaltose (Ferinject): risk of symptomatic hypophosphataemia leading to osteomalacia and fractures[EB/OL]. (2020-11-16) [2026-04-23]. https://www.gov.uk/drug-safety-update/ferric-carboxyma-ltose-ferinject-risk-of-symptomatic-hypophosphataemia-leading-to-osteomalacia-and-fractures.

67. Therapeutic Goods Administration. Ferric carboxymaltose and low blood phosphorous[EB/OL]. (2020-02-27) [2026-04-23]. https://www.tga.gov.au/news/safety-updates/ferric-carboxyma-ltose-and-low-blood-phosphorous.

68. 慕升君, 邢质聪, 张蓓, 等. 基于《中国医疗机构药品评价与遴选快速指南(第二版)》的静脉铁剂多维度量化评价[J]. 药物流行病学杂志, 2026, 35(1): 39-50.MuSJ, XingZC, ZhangB, et al. Multi-dimensional quantitative evaluation of intravenous iron formulations based on a quick guideline for drug evaluation and selection in chinese medical institutions (the 2nd edition)[J]. Chinese Journal of Pharmacoepidemiology, 2026, 35(1): 39‑50. DOI: 10.12173/j.issn.1005-0698.202504069.

69. 邢质聪, 孙福东, 薛青霞, 等. 4种静脉铁剂治疗缺铁性贫血的快速卫生技术评估[J]. 药物流行病学杂志, 2024, 33(9): 1030-1043.XingZC, SunFD, XueQX, et al. Four intravenous iron formulations in the treatment of iron deficiency anemia: a rapid health technology assessment[J]. Chinese Journal of Pharmacoepidemiology, 2024, 33(9): 1030‑1043. DOI: 10.12173/j.issn.1005-0698.202406030.

70. XingZ, MuS, XueQ, et al. Economic evaluation of intravenous iron formulations for patients with iron deficiency anemia: a systematic review[J]. Front Health Serv, 2025, 5: 1690519. DOI: 10.3389/frhs.2025.1690519.

71. HuS, LiuL, PollockRF, et al. Intravenous iron for the treatment of iron deficiency anemia in China: a patient-level simulation model and cost-utility analysis comparing ferric derisomaltose with iron sucrose[J]. J Med Econ, 2022, 25(1): 561-570. DOI: 10.1080/13696998.2022.2065092.

72. 孙文韬, 庄铃香, 马爱霞. 羧基麦芽糖铁治疗中国缺铁性贫血成人患者的成本-效果分析[J]. 中国药房, 2023, 34(22): 2750-2755. [SunWT, ZhuangLX, MaAX. Cost-effectiveness analysis of ferric carboxymaltose for treating iron deficiency anemia in adult Chinese patients[J]. China Pharmacy, 2023, 34(22): 2750‑2755.DOI: 10.6039/j.issn.1001-0408.2023.22.11.

73. ZhangF, ShenA, AhmedW, et al. A cost-utility analysis of ferric derisomaltose versus ferric carboxymaltose in patients with iron deficiency anemia in China[J]. Adv Ther, 2024, 41(11): 4191-4204. DOI: 10.1007/s12325-024-02987-7.

74. 国家统计局. 2025年居民收入和消费支出情况[EB/OL]. (2026-01-19) [2026-04-15]. https://www.stats.gov.cn/sj/zxfb/202601/t20260119_1962321.html.